GH secretagogue comparison
Ipamorelin vs GHRP-2
Compare receptor pharmacology, GH response, appetite effects and evidence maturity rather than declaring a winner.
At a glance
Ipamorelin
GHRP-2
Human evidence
Human evidence includes early PK/GH-response studies and a randomized Phase II postoperative-ileus trial. In that trial, IV ipamorelin 0.03 mg/kg twice daily did not significantly improve the primary or key secondary efficacy endpoints versus placebo.
Small human physiology studies show GH release, increased food intake and activation of ACTH/prolactin pathways.
Research focus
GH-axis physiology and motility research
GH-axis physiology
Regulatory status
Not FDA-approved; FDA lists safety concerns for compounded ipamorelin.
Not FDA-approved; FDA highlights compounding safety uncertainty.
Route / formulation
The Phase II evidence was intravenous in postoperative patients and cannot be transferred to subcutaneous wellness/bodybuilding use.
Acute hormone release does not prove body-composition or performance benefit.
No head-to-head clinical outcome trial identified Compare receptor pharmacology, GH response, appetite effects and evidence maturity rather than declaring a winner.